Biogen Inc. (26)

Browse by Contract Category

Contracts

Employment Agreement, dated November 10, 2022, by and between Biogen Inc. and Christopher A. Viehbacher (Filed With SEC on November 10, 2022)
Biogen Inc. 2006 Non-Employee Directors Equity Plan, as amended (Filed With SEC on May 3, 2022)
Joint Venture Agreement, dated December 6, 2011, by and between Samsung BioLogics Co., Ltd. and Biogen Therapeutics Inc. (f/k/a Biogen Idec Therapeutics Inc.), as amended February... (Filed With SEC on April 22, 2021)
Registration Rights Agreement, dated February 16, 2021, between Biogen Inc. and Deutsche Bank Securities Inc. and Citigroup Global Markets, Inc. with respect to the 3.250% Senior... (Filed With SEC on February 16, 2021)
Letter regarding employment arrangement of Michel Vounatsos dated May 2, 2022 (Filed With SEC on May 3, 2022)
Description of Securities (Filed With SEC on February 3, 2022)
Amended and Restated Biogen Inc. 2019 Performance-Based Management Incentive Plan, effective as of June 2, 2021 (Filed With SEC on July 22, 2021)
Form of 3.250% Senior Notes due 2051, in the form of a Global Note bearing a Regulation S legend (Filed With SEC on February 16, 2021)
Form of 3.250% Senior Notes due 2051, in the form of a Global Note bearing a private placement legend (Filed With SEC on February 16, 2021)
Third Supplemental Indenture, dated February 16, 2021, between Biogen Inc. and U.S. Bank National Association (Filed With SEC on February 16, 2021)
Second Supplemental Indenture, dated April 30, 2020, between Biogen Inc. and U.S. Bank National Association, including the forms of Global Notes attached as Exhibit A and Exhibit... (Filed With SEC on February 3, 2021)
Letter regarding employment arrangement of Chirfi Guindo dated October 12, 2017 (Filed With SEC on February 3, 2021)
Separation Agreement between Biogen Inc. and Jeffrey Capello dated July 16, 2020 (Filed With SEC on October 21, 2020)
Letter regarding employment arrangement of Michael McDonnell dated July 16, 2020 (Filed With SEC on October 21, 2020)
Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective July 13, 2020 (Filed With SEC on October 21, 2020)
Second Supplemental Indenture, dated April 30, 2020, between the Company and U.S. Bank National Association, including the forms of Global Notes attached as Exhibit A and Exhibit... (Filed With SEC on April 30, 2020)
Underwriting Agreement, dated April 27, 2020, by and among the Company, Goldman Sachs & Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the... (Filed With SEC on April 30, 2020)
Description of Securities (Filed With SEC on February 6, 2020)
Credit Agreement, dated as of January 28, 2020, among Biogen Inc., Bank of America, N.A., as administrative agent, swing line lender and the L/C issuer, and the other lenders... (Filed With SEC on February 3, 2020)
Annual Retainer Summary for Board of Directors (effective as of January 1, 2020) (Filed With SEC on October 22, 2019)
Biogen Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective June 19, 2019 (Filed With SEC on July 24, 2019)
Form of performance stock units award agreement (cash settled) under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019) (Filed With SEC on July 24, 2019)
Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019) (Filed With SEC on July 24, 2019)
Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan (for grants commencing in July 2019) (Filed With SEC on July 24, 2019)
Biogen Inc. 2019 Form of Performance-Based Management Incentive Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 (Filed With SEC on April 24, 2019)
Annual Retainer Summary for Board of Directors (Filed With SEC on February 6, 2019)